Identification of human IgG1 variant with enhanced FcRn binding and without increased binding to rheumatoid factor autoantibody

Atsuhiko MaedaChugai Pharmaceutical Co. Ltd., Pharmaceutical Technology Division, Ukima Research Labs., Ukima, Kita-ku, Tokyo, Japan

Yuki IwayanagiChugai Pharmaceutical Co. Ltd., Research Division, Kamakura Research Labs, Kajiwara, Kamakura, Kanagawa, Japan

Kenta HarayaChugai Pharmabody Research Pte. Ltd., Synapse, Singapore

Tatsuhiko TachibanaChugai Pharmaceutical Co. Ltd., Research Division, Kamakura Research Labs, Kajiwara, Kamakura, Kanagawa, Japan

Genki NakamuraChugai Pharmaceutical Co. Ltd., Research Division, Fuji Gotemba Research Labs, Komakado, Gotemba, Shizuoka, Japan

Takeru NambuChugai Pharmaceutical Co. Ltd., Research Division, Fuji Gotemba Research Labs, Komakado, Gotemba, Shizuoka, Japan

Keiko EsakiChugai Pharmaceutical Co. Ltd., Research Division, Fuji Gotemba Research Labs, Komakado, Gotemba, Shizuoka, Japan

Kunihiro HattoriChugai Pharmaceutical Co. Ltd., Research Division, Kamakura Research Labs, Kajiwara, Kamakura, Kanagawa, Japan

Tomoyuki IgawaChugai Pharmaceutical Co. Ltd., Research Division, Fuji Gotemba Research Labs, Komakado, Gotemba, Shizuoka, JapanCorrespondence[email protected]

show all

Identification of human IgG1 variant with enhanced FcRn binding and without increased binding to rheumatoid factor autoantibody

Supplemental_Materials.docx

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Identification of human IgG1 variant with enhanced FcRn binding and without increased binding to rheumatoid factor autoantibody

Supplemental_Materials.docx

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date